A Natural History Study in Participants With DOK7 Congenital Myasthenic Syndromes (CMS)

Congenital Myasthenic Syndrome Clinical Trial

Official title:
Multicenter, Multinational, Natural History Study in Participants With DOK7 Congenital Myasthenic Syndromes

Status Recruiting

Clinical Trial Summary

Participants will attend up to 3 study visits to collect clinical assessments. The assessments will evaluate participants' symptoms and quality of life to understand disease activity in patients with DOK7-CMS better and may inform future study design.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06078553
Study type	Observational
Source	argenx
Contact	Sabine Coppieters, MD
Phone	857-350-4834
Email	clinicaltrials@argenx.com
Status	Recruiting
Phase
Start date	February 13, 2024
Completion date	July 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01203592` - Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes	Phase 1
Recruiting	`NCT01403402` - Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Completed	`NCT05408702` - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed	`NCT01474980` - Pregnancy Outcomes in Congenital Myasthenie Syndrome	N/A
No longer available	`NCT03062631` - Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
No longer available	`NCT02189720` - Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Approved for marketing	`NCT00872950` - 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)